Clinical trial · Interventional
Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy
A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare postoperative nausea and vomiting (PONV) and perioperative outcomes of gynecologic patients undergoing laparoscopic surgery after scheduled administration of intravenous Ramosetron during hospital stays. * Randomized controlled arm : Placebo versus Ramosetron injection * Administration schedule : immediate postoperative status, 12 hrs after surgery, 36hrs after surgery
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Myoma, Ovary Neoplasm, Adenomyosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ramosetron | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- ACTIVE_COMPARATOR
- label
- Ramosetron
- interventionNames
- Drug: Ramosetron
Primary outcomes (1)
- measure
- Incidence or intensity of PONV
- timeFrame
- during postoperative hospital stays (2 days)
Secondary outcomes (1)
- measure
- Adverse reaction associated with Ramosetron injection
- timeFrame
- Postoperatvie 7 days (at OPD based)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age: 18\< or =, = or \<70 with benign gynecologic disease * ASA-Class I-II * No-definite malignancy by US, CT/MRI, CA 125 \< 500IU/ml * Non-smoker Exclusion Criteria: * Conversion to laparotomy * Hx of malignancy * Smoker * Suspicious malignancy
References
Publications (1)
- DERIVEDLi SC, Wang Y, Choi SJ, Jung YS, Han KH, Chung IB, Lee SH. Scheduled injection of ramosetron for prevention of nausea and vomiting following single-port access total laparoscopic hysterectomy: a prospective randomized study. Obstet Gynecol Sci. 2019 Sep;62(5):344-351. doi: 10.5468/ogs.2019.62.5.344. Epub 2019 Jul 23. PMID 31538078